ATHE

Alterity Therapeutics Ltd

• TipRanks·03/30 11:35

  Alterity Therapeutics receives regulatory feedback from FDA regarding ATH434

• Benzinga·03/30 11:26

  Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA

• Reuters·03/30 11:25

  ALTERITY THERAPEUTICS LTD - END-OF-PHASE 2 FDA MEETING ON TRACK FOR MID-2026

• Reuters·03/30 10:09

  Alterity says FDA backs key elements of ATH434 Phase 3 MSA program after Type C meeting

• NASDAQ·03/30 03:21

  Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial

• NASDAQ·03/04 12:58

  Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor

• Reuters·03/04 11:04

  Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor

• TipRanks·03/02 12:29

  Alterity Therapeutics recognizes MSA Awareness Month

• TipRanks·01/30 12:38

  Alterity Therapeutics provides corporate update

• TipRanks·01/21 12:36

  Alterity Therapeutics highlights key 2026 objectives

• Benzinga·01/21 12:27

  Alterity Targets $2.4B Market as Lead Drug Clears Phase 2 and Moves Toward Phase 3

• Reuters·01/21 12:25

  Alterity Therapeutics Completes Phase 2 ATH434 Trial and Prepares for Phase 3 in MSA

• Benzinga·01/09 21:05

  12 Health Care Stocks Moving In Friday's After-Market Session

• Dow Jones·12/17/2025 13:03

  Alterity Therapeutics Initiated at Speculative Buy by Canaccord Genuity

• TipRanks·12/17/2025 12:20

  Alterity Therapeutics initiated with a Speculative Buy at Canaccord